Drug Trial Radar · NCT03819153
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,533
Actual
Start
Jun 17, 2019
Primary completion
Jan 9, 2024
Study completion Jan 9, 2024
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.
Conditions
- Diabetes Mellitus, Type 2
Interventions
SemaglutideDrug
Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
Placebo (semaglutide)Drug
Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV DeathTime frame: From Week 0 up to Week 234
Locations
413 sites in 28 countries. Site status is shown where the registry gives one.
Dr. Terence Hart
Tuscumbia, Alabama
California Inst Of Renal Res
Chula Vista, California
John Muir Physician Network
Concord, California
John Muir Physicians Network
Concord, California
Valley Research
Fresno, California
California Institute of Renal Research
La Mesa, California
First Valley Med Grp Lancaster
Lancaster, California
Clinical Trials Research_Sacramento
Lincoln, California
VA Loma Linda Hlthcr Sys
Loma Linda, California
Long Beach Center For Clinical Research
Long Beach, California
VA Long Beach Healthcare System
Long Beach, California
Academic Medical Research Institute
Los Angeles, California
Valley Renal Medical Group Research
Northridge, California
Desert Oasis Hlthcr Med Group
Palm Springs, California
Saviers Medical Group
Port Hueneme, California
Inland Empire Clin Trials LLC
Rialto, California
Sierra Clinical Research
Roseville, California
California Research Foundation
San Diego, California
N America Res Inst - San Dimas
San Dimas, California
NorCal Endocrinology and Internal Medicine
San Ramon, California
Lundquist Inst-Biomed Innovtn
Torrance, California
San Fernando Valley Hlth Inst
West Hills, California
Rocky Mount Reg VA Med-DN
Aurora, Colorado
Creekside Endocrine Associates, PC
Denver, Colorado
BayCare Medical Group - Endocrinology
Clearwater, Florida
Horizon Rs Grp, Coral Gbls
Coral Gables, Florida
Cesar Figueroa M.D. P.A.
Delray Beach, Florida
Northeast Research Institute
Fleming Island, Florida
Palmetto Medical General Plaza
Hialeah, Florida
Encore Medical Research LLC
Hollywood, Florida
Homestead Associates In Research
Homestead, Florida
Life Spring Research
Miami, Florida
Oceane 7 Medical & Research Center, Inc.
Miami, Florida
International Physicians Research
Miami, Florida
San Marcus Res Clin Miami Lakes
Miami Lakes, Florida
Floridian Clinical Research, LLC
Miami Lakes, Florida
South Broward Research LLC
Miramar, Florida
Suncoast Clinical Research, Inc.
New Port Richey, Florida
Hanson Clinical Research Center
Port Charlotte, Florida
Northeast Research Institute
Saint Augustine, Florida
Showing 40 of 413 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.